IDO1 and neoplasm: At the same time, the authors loaded into these modified PD-1+ EVs an inhibitor of indoleamine 2,3-dioxygenase (IDO) to block a parallel immunosuppressive pathway, which allowed increased tumor infiltration of CD8 + T-cells and tumor regression [94].